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reasonable representation of the selected actual rates. Mortality rates were stratified 
by age. A probabilistic sensitivity analysis (PSA) was performed to account for the 
effect of uncertainty in the model parameters. Results: For the current practice, 
we estimated that annually 75% of CDI cases are new infections; the rest are recur-
rences; 40% of CDI occurs among individuals aged 80+, 41% among 60-79, and 19% 
among those below 60; hospital-based CDI accounted for 69 % of all CDI, while 
community and LTCF based CDI accounted for 26% and 5% of all CDI, respectively. 
The recurrence rates for current antibiotic treatment were estimated at 25.3% and 
35.9% for first and second recurrences, respectively. The recurrence rate for FMT 
was estimated at 10.4%. For the base case, we estimated 79.0 and 64.9 per 100,000 
population cases of CDI for current practice and FMT, respectively. The number of 
deaths is estimated at 5.8 and 4.7 per 100,000 population for current practice and 
FMT, respectively. The results of the cost-effectiveness analysis indicate that in the 
base case, FMT is a dominant strategy. The results of the PSA reveal that for the 
majority of simulations, FMT is dominant (positive incremental QALYs and negative 
incremental cost). ConClusions: The results of the cost-effectiveness analysis 
indicate that FMT appears to be the dominant strategy, with lower costs and better 
outcomes than the existing antibiotic treatments.
PIN72
The ImPorTaNce of SeNSITIvITy aNalySIS IN aSSeSSINg clINIcal aNd 
ecoNomIc ImPacT of NaTIoNal ImmuNIzaTIoN ProgramS: aN examPle 
of SloveNIa
Hren R.1, Delgleize E.2
1GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia, 
22GlaxoSmithKline Vaccines, Wavre, Belgium
objeCtives: To demonstrate the role of sensitivity analysis (SA) in assessing clinical 
and economic impact of national immunization programs. Methods: We applied 
our recent cost-effectiveness model of pneumococcal vaccination to the local data 
in Slovenia, which is particularly notable for high incidence of community-acquired 
pneumonia (CAP) and acute otitis media (AOM). In the model, we followed the cohort 
of 21,938 Slovenian infants over their lifetime and compared two pneumococcal vac-
cine (PCV) options (PHiD-CV and PCV-13) with each other and with a “no vaccination” 
strategy (NVS) from a payer perspective, both at current and parity prices. The model 
simulated vaccine protection against both pneumococcal diseases (invasive, CAP, 
AOM) and AOM related to non-typeable Heamophilus influenzae (NTHi). We performed 
various sensitivity analyses, including probabilistic Monte Carlo simulations by 
employing parameter values derived from clinical trials and post-marketing surveil-
lance data. Results: SA has shown that PHiD-CV vaccine dominated PCV-13 vaccine 
across the range of parameters, both at current and parity prices, and robustness 
of domination was further confirmed by more than 95% out of 1,000 Monte Carlo 
simulations, where PHiD-CV dominated PCV-13. SA when comparing each vaccine 
with NVS showed that at current prices reduction of CAP, AOM, and myringotomy-
procedure incidence by 50% in children younger than 10 years increased incremental 
cost-effectiveness ratio (ICER) from € 4,237 per quality-adjusted life year (QALY) to 
€ 18,917/QALY for PHiD-CV and from € 16,049/QALY to € 35,040/QALY for PCV-13. At 
current prices, vaccination with PHiD-CV dominated NVS when at least 17.5% of 
parents of sick children would take a paid leave, which – in the Slovenian jurisdiction 
– constitute direct costs; in comparison, corresponding ICER for vaccination with PCV-
13 vs. NVS was € 12,306/QALY. ConClusions: Both base case and SA model findings 
suggest that Slovenian authorities would save resources by implementing national 
immunization program of infants with PHiD-CV as a vaccine of choice.
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objeCtives: This study assesses the PAN-genotypic costs-effectiveness of sofos-
buvir compared with standard of care in the Netherlands. Methods: Untreated 
hepatitis C virus (HCV) infection results in chronic liver disease. The prevalence in 
The Netherlands is estimated at 0.1-0.4% with 50% of patients having HCV genotype 
1 (GT1), 10% GT2, 30% GT3 and 10% GT4-5-6. Current standard of care (SoC), regardless 
of genotype consists of weekly subcutaneous pegylated interferon-alpha (PegIFN-α ) 
plus daily oral ribavirin. In GT1, the protease inhibitors telaprevir or boceprevir 
are added. Sofosbuvir (SOF), a novel Direct Antiviral Agent (DAA), has consistently 
demonstrated high rates of sustained virological response (SVR) when given with 
ribavirin±PegIFN-α . This cost-effectiveness evaluation is based on a Markov transi-
tion model, that combines efficacy and safety data from published RCTs with SOF 
and SoC in all genotypes with specific attention for subgroups for whom no alterna-
tives are available (no PegIFN-α eligibility). Medical resource use is based on clinical 
guidelines and expert opinion. Costs include treatment costs, monitoring costs, costs 
for treatment of complications and adverse events as well as productivity loss. The 
model has a lifetime horizon and costs are discounted with 4% and outcomes with 
1.5%. Results are presented for an HCV mono-infected population with 20% cirrhotic 
patients. Results: The incremental QALY gain for SOF was 1.23 in PegIFN-α eligible 
patients and 2.68 in those not eligible for PegIFN-α . The incremental costs were € 25,291 
for PegIFN-α eligible patients and € 89,707 for those not eligible for PegIFN-α . The result-
ing PAN-genotypic ICERs were € 20,487 for PegIFN-α eligible patients and € 33,516 for 
those not eligible for PegIFN-α . ConClusions: PAN-genotypic cost-effectiveness is 
demonstrated for sofosbuvir in the treatment of HCV in the Netherlands.
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were however not considered to be able to replace CE except for MEA (14% reported 
that it could replace CE versus 0% for the others). In countries where CE is not 
formally used, the proportion of experts considering them as relevant was lower 
except for the BOM: RoI (46%), MCDA (46%), QoC (18%), BOM (60%) and MEA (33%). 
Most reported barriers for use of the alternative methods were: no political interest, 
unfamiliarity with these methodologies, and lack of robust input data to conduct 
the evaluation. The method selection was most influenced by the appropriate-
ness to the decision-making question, the country, and the vaccine or disease type 
assessed. ConClusions: Creating awareness on additional economic evaluation 
methods may support and facilitate the vaccine reimbursement decision-making 
process in Europe alongside the current CE analysis.
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objeCtives: Pneumococcal conjugate vaccines are available in the Netherlands 
against pneumococcal disease in infants and adults. This analysis aimed to identify 
an optimal vaccination strategy between infants and adults when the budget is 
constrained. Extensive sensitivity analysis is performed around herd protection on 
Invasive Pneumococcal Disease (IPD) and Community Acquired Pneumonia (CAP) 
resulting from infant vaccination. Methods: We developed an optimization model 
linked to a prevalence-based disease management sub-model. This program allows 
finding an optimal solution given an objective function (minimize cases; minimize 
quality-adjusted life-years (QALYs) lost; minimize life-years (LYs) lost) under budget 
constraints. Vaccine efficacy (VE) is based on clinical trial data. The model is run for 
different scenarios seeking for minimum indirect effect on IPD and on CAP in the 
whole population needed to keep infant vaccination as the optimal intervention, 
given a constrained budget. Results: With the current disease burden and vaccine 
coverage rate in the Netherlands and considering an overall VE in adults against 
CAP of 4.5% and against IPD of 37% (estimates based on CAPITA clinical trial results), 
the model shows that vaccinating infants is the optimal strategy that minimizes 
pneumococcal-related events when compared with adult vaccination. If the objec-
tive is to minimize QALYs lost, vaccinating infants remains the optimal selection 
as long as the net indirect effect is ≥ 2% on CAP or ≥ 3% on IPD. When the objective 
is to minimize LYs lost, the minimum indirect effect should be ≥ 3% on CAP or ≥ 7% 
on IPD. Sensitivity analyses show that even if CAP VE in adults is 3 times higher, the 
estimated minimum indirect effect needed is still below the one obtained with the 
first pneumococcal conjugate vaccine. ConClusions: The optimal strategy within 
a constrained budget is to maintain infant vaccination instead of initiating elderly 
vaccination, given the reported evidence of indirect protection.
PIN70
coST-effecTIveNeSS aNalySIS of a ShINgleS vaccINaTIoN Program To 
PreveNT herPeS zoSTer aNd PoST- herPeTIc NeuralgIa IN The SPaNISh 
SeTTINg
Álvarez Pasquín M.J.1, Cisterna R.2, Gil de Miguel A.3, López-Belmonte J.L.4, Préaud E.5,  
Trejo A.4
1Centro de Salud Santa Hortensia, Madrid, Spain, 2Basurto Hospital, Bilbao, Spain, 3Universidad 
Rey Juan Carlos, Alcorcon, Spain, 4Sanofi Pasteur MSD Spain, Madrid, Spain, 5Sanofi Pasteur 
MSD, Lyon, France
objeCtives: A live-attenuated vaccine aimed at preventing herpes zoster (HZ) and 
post-herpetic neuralgia (PHN) is available in Europe for immunocompetent adults 
aged ≥ 50 years. The study objective is to assess the incremental cost-effectiveness 
ratio (ICER) of a vaccination program for this population in Spain when compared 
against the current strategy of no-vaccination. Methods: A state-transition 
Markov model has been developed to simulate the natural history of HZ and PHN 
and the lifetime effects of vaccination. Several health states are defined including 
good health, HZ, PHN and death. HZ and PHN health states are divided to reflect 
pain severity. The Markov cycle was 1 month and lifetime horizon. The HZ vaccine 
lifetime duration (waning rate of 8.3%) and a PHN vaccine duration of 10 years. PHN 
proportion was obtained from Cebrián-Cuenca (2011) and adjusted to reflect the 
incidence of PHN among HZ patients with pain. The vaccine coverage rate estimated 
was 30%, considering discount rates of 3% for costs and utilities. The strength of the 
results was confirmed with a probabilistic analysis based on Monte Carlo simula-
tion. Results: A vaccination strategy compared to a no-vaccination resulted in 
12.659€ /QALY and 11.926€ /QALY under third-party payer perspective and societal 
perspective respectively for the population aged ≥ 50 years. ICERs were within the 
commonly accepted thresholds of 30.000£/QALY (36.000€ /QALY) gained in the UK. 
Sensitivity analyses showed that the model was most sensitive to discount rates 
and duration of vaccine protection. The lowest ICER was observed for the 70-74 years 
age group (6.657€ /QALY under third-party payer perspective). ConClusions: In 
Spain, a shingles vaccination strategy in older population would be a cost-effective 
alternative in comparison with no vaccination, due to an ICER of 12.659€ /QALY from 
the third-party payer perspective.
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objeCtives: To estimate the cost-effectiveness of Fecal Microbiota Transplant 
(FMT) for Clostridium difficile infection (CDI) as compared to the current practice 
comprising of antibiotic treatments. Methods: We developed a decision analytic 
model to compare strategies for the management of CDI, by age, gender, and three 
sources of infection: hospitals, communities, and long-term care facilities (LTCF). We 
performed validation analyses to demonstrate that the predicted CDI rates were a 
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is projected to be cost-savings against PR alone in the majority of CHC genotype 
1 patients, regardless of treatment history.
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objeCtives: Economical evaluation of Stribild in Turkey, which is a single tablet 
regimen indicated for the treatment of HIV-1 infection in adults aged 18 years and 
over who are antiretroviral treatment naive or are infected with HIV-1 without 
known mutations associated with resistance to any of the three antiretroviral agents 
in it. Methods: STRIBILD™ was compared with various treatment options; teno-
fovir DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ 
ritonavir+lopinavir (FTC/TDF+LPV/r), tenofovirDF+emtricitabine+nevirapine (FTC/
TDF+NVP), tenofovir DF+emtricitabine+darunavir (FTC/TDF+DRV+r), tenofovir 
DF+emtricitabine+raltegravir (FTC/TDF+RAL), lamivudine+zidovudine+efavirenz 
(3TC/AZT+EFV), lamivudine+zidovudine+ritonavir+lopinavir (3TC/AZ+LPV/r), lam
ivudine+zidovudine+nevirapine (3TC/AZT+NVP). The adherence rates were calcu-
lated from the increase rate in CD4 cell count and the risk of hospitalization as 
the effectiveness values. The data were taken from patient files from Hacettepe 
University that consists of 252 patients and 12 year follow-ups with an outpatient 
clinic, interventions, laboratory and imaging tests, medication usage, side effects, 
comorbidity’s diseases and their treatments and complications. The costs of treat-
ment of diseases were calculated by cost of disease methodology. Average annual 
cost per patient is calculated for health care technologies. Health technology effec-
tiveness values are found from the literature review. Incremental cost-effectiveness 
ratio (ICER) was used for the comparison. Results: According to comparison of rate 
of compliance to treatment, STRIBILD™ was cost effective against 3TC/AZT+EFV 
(2157.2 TL), FTC/TDF+LPV/r (612.7 TL), FTC/TDF+NVP (951.9 TL), FTC/TDF+DRV+r 
(544.28 TL) and cost saving aganist FTC/TDF+RAL (-166,22 TL). According to the rate 
of risk of hospitalization, STRIBILD™ was cost effective against 3TC/AZT+EFV (517.7 
TL), FTC/TDF+LPV/r (318.6 TL), FTC/TDF+NVP (495 TL), FTC/TDF+DRV+r (283 TL), 3TC/
AZT+EFV (632,4 TL), 3TC/AZ+LPV/r (425.6 TL), 3TC/AZT+NVP (591.2 TL). According to 
the increase rate in CD4 cell count and over 95% of compliance rate, STRIBILD™ was 
cost effective against FTC/TDF+EFV (392.2 TL) and cost saving against FTC/TDF+RAL 
(-308.7 TL), respectively. ConClusions: HIV is a life-threatening disease with in 
terms of major public health problem globally.. In this study, STRs in comparison 
of combination treatment strategies, has higher compliance rates, better outcomes 
and lower health care costs.
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objeCtives: The objective was to assess the cost-effectiveness of 3 scenarios for the 
diagnosis of TB among PLWH depending on CD 4+ count and their influence to treat-
ment pathway and outcomes. Methods: A deterministic decision analytic model 
was designed for three TB possible searching scenarios in three hypothetical cohorts 
of 1000 PLWH with different CD 4+ count (< 200, 200-499, > 500). The following scenar-
ios were examined: ‘‘Base’’— the current diagnostic scheme, according the National 
Program; ‘‘Addition’’—the current diagnostic scheme and Xpert/Rif; ‘‘Replacement’’ 
– Xpert/Rif test only. Inputs’s from the country report and Russian epidemiologic 
data. The analysis was conducted from the Russia health care perspective with an 
analytic horizon of 2 years. Results: CD 4+ < 200 cohort CER in “Base” is 541817, 
in “Addition” – 643771, “Replacement” – 648087. Additional cost per one success-
fully treated RUB1123K (23893 € ), cost per death averted pts RUB5035K (107127 € ), 
in “Addition” compared to “Base”. CD 4+ 200 – 499 cohort CER in “Base” is 390693, 
in “Addition” – 550615, “Replacement” – 665529. Additional cost per one success-
fully treated RUB5422K (115361 € ), cost per death averted pts RUB5226K (111191€ ) 
in “Addition” compared to “Base”. CD 4+ > 500 cohort CER in “Base” is 408581, in 
“Addition” – 642137, “Replacement” – 597470. Additional cost per one success-
fully treated RUB6093K (129638 € ), cost per death averted pts RUB6649K (141468 € ) 
in “Addition” compared to “Base”. ConClusions: If it needs to solve, which of 
diagnostic scenarios we finance, we should take into account not only CER, but 
opportunity to miss TB cases. Using “Addition” is especially effective for diagnostic 
research in CD 4+ < 200 cohort.
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objeCtives: Single-Tablet Regimens (STR) therapies are effective to maintain high 
adherence and improves HAART efficacy. Methods: We evaluated viro-immunologic 
outcomes, Quality of Life (QoL), and costs of an unselected cohort of patients switch-
ing from TDF/FTC/EFV STR (≥ 6 months duration) to TDF/FTC/RPV STR. The considered 
outcome measures were quality-adjusted life years (QALYs) as measured with the 
EQ5D questionnaire and the overall direct health costs. 64 patients with a baseline 
viral load < 50 copies/ml were randomized to immediately switch therapy or to con-
tinue TDF/FTC/EFV for 4 months and then switch to TDF/FTC/RPV. 6 patients in the 
deferred switch group did not change cART. Results: Patients were mostly males 
(73.4%) with a mean age of 46 years, a baseline mean HIV-RNA of 6.42 copies/ml and 
a mean baseline CD4 count of 588 cells/μ L. The mean cost per patient resulted € 2,563 
for STR with RPV arm and € 2,572 for STR with EFV arm. After 4 months the mean 
objeCtives: Since 2009, 12-year-old Dutch teenage girls are vaccinated against 
human papillomavirus (HPV) infection. The current uptake of HPV vaccination, being 
approximately 60% nowadays, is however comparatively low. Consequently, a large 
group of women are still at risk of developing HPV-induced cervical cancer later on in 
life. Therefore, alternative HPV vaccination scenarios have been proposed, in addition 
to the existing programme, to provide additional protection against cervical cancer. 
Here, we assessed the cost-effectiveness of three different vaccination scenarios: (i) 
increased coverage of the existing programme, (ii) vaccination of girls at an older age, 
and (iii) vaccination of 12-year-old boys. Methods: A dynamic model was used to 
estimate the full health-economic consequences of the existing programme with 
and without the above alternative scenarios. Costs and health effects of the alterna-
tive scenarios, expressed as life years (LYs) or quality-adjusted life years (QALYs) 
gained, were compared with the outcomes of the existing programme. In sensitivity 
analyses, the robustness of the model-predicted outcomes was evaluated. Results: 
We found the incremental cost-effectiveness ratio of the existing HPV vaccination 
programme to be € 9,500 per QALY gained. The cost-effectiveness of the alternative 
programs highly depends on the coverage at 12 years of age. The cost-effectiveness 
of girls 24 years of age remained below € 50,000/QALY if coverage at 12 years of age 
increased up to 70%. Cost-effectiveness of vaccination boys at 12 years of age becomes 
unfavourable if coverage among 12-year old girls increases. ConClusions: From a 
health-economic perspective, alternative HPV vaccination programmes should be 
considered in the Netherlands to further reduce the burden of HPV-induced cancer. 
Until a high coverage among 12-year old girls in reached the addition of older girls to 
the current vaccination program is most cost-effective.
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objeCtives: Utilization of routine viral load (VL) and CD4 cell count coupled to clini-
cal monitoring of HIV patients needs to be carefully deliberated in cost-effective-
ness, especially for resource-limited countries. The review was aimed to evaluate 
and compare the cost-effectiveness of these strategies individually and in combina-
tion. Methods: A literature review was conducted for studies published in English 
from 2004 to 2014 on Pubmed, Web of Science, Ovid, Google Scholar, with keywords 
HIV, viral load, CD4, economic evaluation, and cost analysis. All underwent assign-
ment of Levels of Evidence (LOE) by Oxford Center for Evidence-Based Medicine 
(CEBM), as well as Drummond scoring criteria. Results: Thirty English publications 
were identified, including 14 modeling studies, 7 randomized clinical trials (RCT’s), 
and 5 cohort studies among others. A total of 24 were based on resource-limited 
settings such as Africa, Latin America, and Asia. Compared with CD4, VL alone had 
incremental cost-effectiveness ratios (ICER’s) ranging from $2520/LY to $3570/life year 
(LY); while that of CD4 alone compared to clinical monitoring was from $-13134/LY 
to $5768/quality-adjusted life year (QALY). The combination of CD4 and VL, which is 
recommended in real-life practice, compared to CD4 alone yielded ICER’s ranging from 
$3956/QALY to $16139/QALY. The cost-effectiveness of these strategies was affected 
by factors such as the reference threshold for ICER, costs and monitoring regimens 
of the strategies and antiretroviral treatment. ConClusions: From the studies, it 
is critical to evaluate the cost-effectiveness of CD4 compared with VL contextually, 
with CD4 being more appropriate in resource-limited settings. VL is associated with 
improved benefit, however when used in combination with CD4, is usually not cost-
effective. Compared with clinical monitoring alone CD4 usually produces greater 
cost-effectiveness.
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objeCtives: Current Thai guidelines reimburse peginterferon/ribavirin (PR) com-
bination treatment for patients infected with all genotypes of chronic hepatitis 
C (CHC), based on the results of cost-effectiveness studies. Two trials, SPRINT-2 
and RESPOND-2, have demonstrated that treatment with Boceprevir (BOC) in 
addition to PR results in significantly higher sustained virologic response rates 
than the current standard of care, PR alone for 48 weeks, in both treatment naïve 
and treatment experienced CHC genotype 1 patients. The aim of our analysis 
was to evaluate the cost-effectiveness of BOC-based treatment compared with 
PR alone from the perspective of the policy maker in Thailand over a lifetime 
horizon. Methods: A decision analytic model was developed to simulate the 
treatment strategies described in the BOC label (BOC/PR) and PR alone, and to 
describe the natural history of CHC to make projections beyond the treatment 
phase. Separate analyses were conducted based on patients’ treatment history 
and cirrhosis status. Patient characteristics were obtained from SPRINT-2 and 
RESPOND-2. Treatment characteristics including efficacy and the rate of side 
effects were obtained from subset analyses of these trials. Transition probabili-
ties, costs, and health state utilities were obtained from previously studies. We 
projected the lifetime cumulative incidence of CHC-related liver complications 
– decompensated cirrhosis, hepatocellular carcinoma, liver-transplantation, liver-
related mortality - discounted costs and QALYs associated with each treatment 
strategy. The incremental cost-effectiveness ratio was also assessed. Results: 
For treatment naïve and treatment experienced patients, BOC/PR treatment is 
projected to reduce the incidence of CHC-related liver complications by 43-44% 
and 47-51%. BOC/PR is projected to be less expensive and result in increases of 
0.13-2.62 QALYs for all non-cirrhotic patients and cirrhotic treatment-experienced 
patients. Cirrhotic treatment naïve patients was the only subgroup in which cost-
effectiveness was not demonstrated. ConClusions: In the Thai setting, BOC/PR 
